Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications.

Saved in:
Bibliographic Details
Title: Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications.
Authors: Hunter Hall, Rafe1 (AUTHOR) rafe.hall@okstate.edu, Wright, Carson L.1 (AUTHOR), Hughes, Griffin K.1 (AUTHOR), Peña, Andriana M.1 (AUTHOR), Ladd, Chase1 (AUTHOR), Gardner, Brooke1 (AUTHOR), McIntire, Ryan1 (AUTHOR), Ferrell, Matt2 (AUTHOR), Rubenstein, Jane3 (AUTHOR), Tuia, Jordan4 (AUTHOR), Haslam, Alyson4 (AUTHOR), Prasad, Vinay4 (AUTHOR), Vassar, Matt1,5 (AUTHOR)
Source: Clinical Therapeutics. Jun2024, Vol. 46 Issue 6, pe107-e113. 7p.
Database: Academic Search Ultimate
Description
ISSN:01492918
DOI:10.1016/j.clinthera.2024.04.006